Illumina, Inc. (ILMN)

116,69 -1,60 (-1,35%) Alla chiusura: 04:00PM EDT

Illumina, Inc.

5200 Illumina Way
San Diego, CA 92122
United States
858 202 4500
https://www.illumina.com

Settore/i: Healthcare
Settore: Diagnostics & Research
Impiegati a tempo pieno: 10.590

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Jacob Thaysen Ph.D.	CEO & Director	796,63k	N/D	1975
Ms. Carissa L. Rollins	Chief Information Officer	693,52k	N/D	1970
Mr. Charles E. Dadswell Esq.	Senior VP & General Counsel	1,03M	N/D	1959
Stephanie Campos	President	N/D	N/D	N/D
Mr. Ankur Dhingra	Chief Financial Officer	N/D	N/D	1976
Mr. Kevin Carl Pegels	Chief of Global Operations	N/D	N/D	1968
Mr. Scott Ericksen	VP & Chief Accounting Officer	N/D	N/D	1973
Dr. Steven Barnard Ph.D.	Chief Technology Officer	N/D	N/D	N/D
Ms. Sallilyn Schwartz	Vice President of Investor Relations	N/D	N/D	N/D
Mr. Jakob Wedel	Chief Strategy & Corporate Development Officer and CEO Chief of Staff	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Governance aziendale

L'ISS Governance QualityScore di Illumina, Inc. al 1 aprile 2024 è 10. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 8; diritti degli azionisti: 7; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.